Published 2018
| Version v1
Publication
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Creators
- Lawlor, Brian
- Segurado, Ricardo
- Kennelly, Sean
- Olde Rikkert, Marcel G M
- Howard, Robert
- Pasquier, Florence
- Börjesson-Hanson, Anne
- Tsolaki, Magda
- Lucca, Ugo
- Molloy, D William
- Coen, Robert
- Riepe, Matthias W
- Kálmán, János
- Kenny, Rose Anne
- Cregg, Fiona
- O'Dwyer, Sarah
- Walsh, Cathal
- Adams, Jessica
- Banzi, Rita
- Breuilh, Laetitia
- Daly, Leslie
- Hendrix, Suzanne
- Aisen, Paul
- Gaynor, Siobhan
- Sheikhi, Ali
- Taekema, Diana G
- Verhey, Frans R
- Nemni, Raffaello
- Nobili, Flavio
- Franceschi, Massimo
- Frisoni, Giovanni
- Zanetti, Orazio
- Konsta, Anastasia
- Anastasios, Orologas
- Nenopoulou, Styliani
- Tsolaki-Tagaraki, Fani
- Pakaski, Magdolna
- Dereeper, Olivier
- de la Sayette, Vincent
- Sénéchal, Olivier
- Lavenu, Isabelle
- Devendeville, Agnès
- Calais, Gauthier
- Crawford, Fiona
- Mullan, Michael
Contributors
Others:
- Lawlor, Brian
- Segurado, Ricardo
- Kennelly, Sean
- Olde Rikkert, Marcel G M
- Howard, Robert
- Pasquier, Florence
- Börjesson-Hanson, Anne
- Tsolaki, Magda
- Lucca, Ugo
- Molloy, D William
- Coen, Robert
- Riepe, Matthias W
- Kálmán, Jáno
- Kenny, Rose Anne
- Cregg, Fiona
- O'Dwyer, Sarah
- Walsh, Cathal
- Adams, Jessica
- Banzi, Rita
- Breuilh, Laetitia
- Daly, Leslie
- Hendrix, Suzanne
- Aisen, Paul
- Gaynor, Siobhan
- Sheikhi, Ali
- Taekema, Diana G
- Verhey, Frans R
- Nemni, Raffaello
- Nobili, Flavio
- Franceschi, Massimo
- Frisoni, Giovanni
- Zanetti, Orazio
- Konsta, Anastasia
- Anastasios, Orologa
- Nenopoulou, Styliani
- Tsolaki-Tagaraki, Fani
- Pakaski, Magdolna
- Dereeper, Olivier
- de la Sayette, Vincent
- Sénéchal, Olivier
- Lavenu, Isabelle
- Devendeville, Agnè
- Calais, Gauthier
- Crawford, Fiona
- Mullan, Michael
Description
This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/927170
- URN
- urn:oai:iris.unige.it:11567/927170
Origin repository
- Origin repository
- UNIGE